Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea

September 12, 2024 – Oncopeptides today announces it has signed an exclusive license and supply agreement with SCBIO Inc., a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea.

More info and Q&A for investors

Oncopeptalks on South Korea, growth and pipeline

September 12, 2024 – David and Sofia discusses the recent announcement on South Korea as well as some questions following the recent Q2 report presentation.

Watch the video here

Company news

Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea

September 12, 2024

Oncopeptides today announces it has signed an exclusive license and supply agreement with SCBIO Inc., a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea.

Read more

Lotta Larsson joins Oncopeptides as new Head of Human Resources

September 9, 2024

Lotta Larsson recently joined Oncopeptides as its new Head of Human Resources and part of the company leadership team, replacing Sara Svärdgren who has chosen to resign after 6 years in the role.

Read more

Oncopeptides expands WODA partnership with addition of Africa and Eurasia

September 4, 2024

Oncopeptides and Veld Pharmaceuticals GmbHand Slavpharma GmbH has announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti in Sub-Saharan Africa, with focus on South Africa, and Eurasia.

Read more

Science news

First patient enters real-world data study in Germany

July 22, 2024

Oncopeptides recently announced entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients.

Read more

Oncopeptides selects first candidate drug from its SPiKE platform

June 27, 2024

Oncopeptides recently announced that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected.

Read more

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

May 16, 2024

Oncopeptides today announces that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Controversies in Multiple Myeloma (COMy), to be held on May 23-26.

Read more

Investor news

Oncopeptalks on South Korea, growth and pipeline

September 12, 2024

David and Sofia discusses the recent announcement on South Korea as well as some questions following the recent Q2 report presentation.

Read more

Oncopeptides presented at Aktiespararna event - theme Life Science

August 29, 2024

Oncopeptides Director of IR and Communications David Augustsson recently presented the company at the Aktiespararna event themed Life Science.

Read more

Invitation to presentation of the Q2 report 2024

August 8, 2024

Oncopeptides AB will publish the report for the second quarter of 2024, at 08:00 CET on August 14, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session, at 09:00 CET the same day.

Read more

All Company news

All Science news

All Investor news

Press release - September 12, 2024

Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea

Read press release

Latest press releases

All press releases

Upcoming events

2024-10-08 - 2024-11-06

Silent Period

Other

2024-11-07

Interim Report Q3 2024

Report

2025-01-28 - 2025-02-26

Silent period

Other

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

CEO Sofia Heigis - Oncopeptides AB

Released August 14, 2024

Oncopeptides publishes Q2 report 2024

Read report

Download

“60 percent sales growth versus Q1 and pipeline progresses”

CEO Sofia Heigis

 

See the Webcast

The webcast presentation in PDF

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Q3 interim report 2024 will be published November 7, 2024

Oncopeptides via e-mail